The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Efficacy and Safety of the Novel Selective Nicotinic Acetylcholine Receptor Partial Agonist, Varenicline, for Smoking Cessation
Abstract
BACKGROUND: The selective nicotinic acetylcholine receptor partial agonist, varenicline tartrate, represents a novel type of therapy for smoking cessation. This study evaluated the efficacy, safety, and tolerability of 4 varenicline dose regimens, 2 with progressive dosing over the first week (eg, titrated) and 2 with a fixed dosing schedule (eg, non-titrated), for promoting smoking cessation. METHODS: This multicenter, double-blind, placebo-controlled study randomized healthy smokers (aged 18-65 years) to varenicline tartrate, 0.5 mg twice daily nontitrated (n = 129), 0.5 mg twice daily titrated (n = 130), 1.0 mg twice daily nontitrated (n = 129), 1.0 mg twice daily titrated (n = 130), or placebo (n = 129) for 12 weeks to aid in smoking cessation. A 40-week follow-up period assessed long-term efficacy. The primary efficacy measures were the carbon monoxide-confirmed 4-week continuous quit rates by pooled dosage group for weeks 4 through 7 and 9 through 12 and the continuous abstinence rates for weeks 9 through 52. RESULTS: Weeks 9 through 12 continuous quit rates were greater in the 1.0-mg group (49.4%) and the 0.5-mg group (44.0%) vs placebo (11.6%; P<.001 vs both doses). Weeks 9 through 52 abstinence rates were greater in the 1.0-mg group (22.4%; P<.001) and the 0.5-mg group (18.5%; P<.001) vs placebo (3.9%). Varenicline was generally well tolerated, with nausea occurring in 16% to 42% of varenicline-treated subjects. Reports of nausea were lower for the titrated vs nontitrated dosing and infrequently led to medication discontinuation. CONCLUSION: Varenicline tartrate, 0.5 mg and 1.0 mg twice daily, is efficacious for smoking cessation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These trials document treatment-related reductions in smoking urges and withdrawal-related negative affect (4, 5, 9), as well as reduced smoking reward during a lapse (10).”
From Varenicline improves mood and cognition during smoking abstinence (2009) · cites this paper as [10]
In the citing paper
“The 7-day point prevalence was 37% vs. 8%, respectively at week 52 (108).”
From Tobacco addiction (2008) · cites this paper as [108]
Citations
Cites
The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738
Signs and Symptoms of Tobacco Withdrawal
Hughes, J. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800030107013 · Cited by 1,669
Estimates of global mortality attributable to smoking in 2000
Ezzati, M., & Lopez, A. D. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14338-3 · Cited by 1,247
Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation
Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, E. P., Huang, J., Sands, S. B., Davis, T. I., Lebel, L. A., Fox, C. B., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050069n · Cited by 930
Fiore, M. (2000) · Respiratory care · doi:10.1177/002013240004501006 · Cited by 773
Schultz, H. (1998) · Annals of Saudi Medicine · doi:10.5144/0256-4947.1998.195 · Cited by 430
Tashkin, D., Kanner, R. E., Bailey, W. C., Buist, S. A., ANDERSON, P. J., Nides, Gonzales, D. H., Dozier, G., Patel, M., & Jamerson, B. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04724-3 · Cited by 412
Transdermal Nicotine for Smoking Cessation
Christen, A. G. (1991) · JAMA · doi:10.1001/jama.1991.03470220049025 · Cited by 318
Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
Rose, J. E., Behm, F. M., & Westman, E. C. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.3.331 · Cited by 159
Wagena, E. J., Knipschild, P. G., Huibers, M. J. H., Wouters, E. F. �., & van Schayck, O. C. P. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.19.2286 · Cited by 141
Faessel, H. M., Smith, B. J., Gibbs, M. A., Gobey, J. S., Clark, D. J., & Burstein, A. H. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006290669 · Cited by 106
Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale
Cappelleri, J. C., Bushmakin, A. G., Baker, C. L., Merikle, E. P., Olufade, A. O., & Gilbert, D. G. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43712 · Cited by 75
Effectiveness of a transdermal nicotine system in smoking cessation studies.
Abelin, T., Ehrsam, R., Bühler-Reichert, A., Imhof, P., Müller, P., Thommen, A., & Vesanen, K. (1989) · PubMed · Cited by 75
Foulds, J. (1993) · Archives of Family Medicine · doi:10.1001/archfami.2.4.417 · Cited by 65
Flagged first, then by citations
Cited by
Sorted by citations
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Stead, L., & Lancaster, T. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub2 · Cited by 747
O’Donnell, D. E., Aaron, S. D., Bourbeau, J., Hernandez, P., Marciniuk, D. D., Balter, M. S., Ford, G. T., Gervais, A., Goldstein, R. S., Hodder, R., et al. (2007) · Canadian Respiratory Journal · doi:10.1155/2007/830570 · Cited by 693
Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533
Weight gain in smokers after quitting cigarettes: meta-analysis
Aubin, H.-J., Farley, A., Lycett, D., Lahmek, P., & Aveyard, P. (2012) · BMJ · doi:10.1136/bmj.e4439 · Cited by 510
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis
Wu, P., Wilson, K., Dimoulas, P., & Mills, E. J. (2006) · BMC Public Health · doi:10.1186/1471-2458-6-300 · Cited by 484
Metadata
- Authors
- Oncken, C.
- Affiliations
- UConn Health (US)
- Corresponding author
- Oncken, Cheryl
- ORCID
- Oncken, Cheryl
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2006-08-14
- Volume
- 166
- Issue
- 15
- Pages
- 1571
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2113308458
- Cited by
- 380
- References
- 14
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 7 · 2023: 8 · 2022: 4 · 2021: 9 · 2020: 13 · 2019: 7 · 2018: 13 · 2017: 9 · 2016: 15 · 2015: 28 · 2014: 23 · 2013: 17 · 2012: 28
- FWCI
- 26.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nicotinic Acetylcholine Receptors Study
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- varenicline, smoking cessation, dose titration, abstinence rates, nausea, drug safety, nicotine dependence
- MeSH terms
- Varenicline, Adolescent, Adult, Aged, Benzazepines, Double-Blind Method, Female, Humans, Male, Middle Aged, Quinoxalines, Tobacco Use Disorder, Smoking Cessation, Treatment Outcome, Nicotinic Agonists, Nicotinic Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
